VICO THERAPEUTICS
Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarily affecting girls that enable clients with providing therapy for it.
VICO THERAPEUTICS
Industry:
Health Care Medical Pharmaceutical
Founded:
2019-01-01
Address:
Leiden, Zuid-Holland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.vicotx.com
Total Employee:
11+
Status:
Active
Contact:
+31 71 2036800
Email Addresses:
[email protected]
Total Funding:
115.38 M USD
Technology used in webpage:
Google Maps Google Maps API Combell
Similar Organizations
Aristea Therapeutics
Aristea Therapeutics is a developer of novel therapies created for autoimmune diseases.
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Entasis Therapeutics
Entasis Therapeutics is developing a portfolio of innovative cures.
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Seroba Life Sciences
Seroba Life Sciences investment in Series B - Vico Therapeutics
Droia Ventures
Droia Ventures investment in Series B - Vico Therapeutics
Pureos Bioventures
Pureos Bioventures investment in Series B - Vico Therapeutics
EQT Life Sciences
EQT Life Sciences investment in Series B - Vico Therapeutics
Ackermans & van Haaren
Ackermans & van Haaren investment in Series B - Vico Therapeutics
Eurazeo
Eurazeo investment in Series B - Vico Therapeutics
Kurma Partners
Kurma Partners investment in Series B - Vico Therapeutics
Polaris Partners
Polaris Partners investment in Series B - Vico Therapeutics
Pureos Bioventures
Pureos Bioventures investment in Series B - Vico Therapeutics
Eurazeo
Eurazeo investment in Series B - Vico Therapeutics
Key Employee Changes
Official Site Inspections
http://www.vicotx.com Semrush global rank: 7.82 M Semrush visits lastest month: 701
- Host name: linweb416.webhosting.be
- IP address: 5.134.4.115
- Location: Merelbeke Belgium
- Latitude: 51.0015
- Longitude: 3.7433
- Timezone: Europe/Brussels
- Postal: 9820
More informations about "Vico Therapeutics"
VICO Therapeutics - VICO Therapeutics
The VICOMERTM antisense oligonucleotide platform offers multiple different mechanisms of action, enabling us to design RNA modulating therapeutics to address specific genetic defects …See details»
About - VICO Therapeutics
VICO Therapeutics brings innovative oligonucleotide based RNA modulating therapeutics to patients suffering from rare CNS disorders.See details»
VICO Therapeutics B.V | Leiden Bio Science Park - lbsp.nl
Together with a team of skilled scientists and drug development professionals, VICO’s focus is on development of RNA modulating therapies for rare neurological disorders, with initial focus on …See details»
Vico Therapeutics Appoints Micah Mackison as Chief …
LEIDEN, Netherlands, Aug. 1, 2022 /PRNewswire/ — Vico Therapeutics B.V., a neurology-focused genetic medicine company, today announced the appointment of Micah Mackison as Chief Executive Officer. Mr. Mackison brings significant …See details»
Vico Therapeutics - Crunchbase Company Profile
Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies. Vico Therapeutics received complementary Series B funding totaling €65.8 million ($70.7 million) from Seroba and Kurma Partners. Additionally, Vico …See details»
VICO Therapeutics B.V. | LinkedIn
Vico Therapeutics is committed to advancing RNA modulating therapies for patients with severe, genetic neurological disorders. Vico is initially targeting spinocerebellar ataxia types 3 and 1 and...See details»
Vico Therapeutics - EQT Group
6 days ago · Bringing knowledge, experience and science together to discover, develop and deliver therapies for CNS disorders. Subscribe to EQT's press releases, regulatory press releases and updates.See details»
Vico Therapeutics - VentureRadar
Develops innovative oligonucleotide-based RNA modulating therapeutics for rare CNS disorders, founded by experienced entrepreneurs and scientists in 2019.See details»
Biotech Vico Therapeutics raises $31 million (€27 …
LEIDEN, Netherlands, July 29, 2020 /PRNewswire/ -- Vico Therapeutics, a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological...See details»
US FDA and European Commission grants VICO Therapeutics …
Aug 26, 2021 · VICO’s product, SCA therapy VO659, is designed to suppress faulty proteins that cause SCAs, thereby slowing or halting disease progression. In February 2021, VICO …See details»
Dosing Commenced in Phase 1/2a Trial of VO659 in Huntington …
Apr 7, 2023 · In recent news, Vico Therapeutics announced that the first patient has been dosed in a phase 1/2a clinical study evaluating its investigational agent VO659 for the treatment of …See details»
Biotech VICO Therapeutics raises $31 million (€27 million) in Series …
Jul 29, 2020 · Leiden, The Netherlands, 29 July 2020 – VICO Therapeutics, a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating …See details»
Vico Therapeutics - Craft
Vico Therapeutics is a company that develops ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS …See details»
Vico Therapeutics Announces First Patient Dosed in Phase 1/2a …
Vico Therapeutics B.V. recently announced the first patient has been dosed in a Phase 1/2a clinical study evaluating VO659 for the treatment of Huntington’s disease (HD), …See details»
VICO Therapeutics - Overview, News & Similar companies
Oct 10, 2022 · VICO Therapeutics contact info: Phone number: +31 712036800 Website: www.vicotx.com What does VICO Therapeutics do? VICO Therapeutics is a Leiden, the …See details»
Huntington’s Disease Clinical Trials Corner: March 2024
Mar 29, 2024 · In this edition of the Huntington’s Disease Clinical Trials Update, we expand on the ongoing program from VICO Therapeutics and on the recently terminated VIBRANT-HD …See details»
Privacy Policy - VICO Therapeutics - vicotx.com
Feb 6, 2020 · VICO Therapeutics. (“us”, “we”, or “our”) operates the https://vicotx.com/ website (the “Service”). This page informs you of our policies regarding the collection, use, and …See details»
Vico Therapeutics Company Information - Funding, Investors, and …
Get information on funding, investors, industries, and more for Vico Therapeutics. See Vico Therapeutics company profile and funding data.See details»
VO659 designado medicamento huérfano: Terapia en …
La FDA de EE. UU. y la Comisión Europea otorgan a VICO Therapeutics la designación de medicamento huérfano para VO659, una terapia en investigación para la ataxia …See details»
National Ataxia Foundation Announces Launch of NAF Drug …
About NAF: NAF is a nonprofit organization established in 1957 to help persons with Ataxia and their families. The Foundation’s primary purpose is to support Ataxia research, provide vital …See details»